BioCentury
ARTICLE | Targets & Mechanisms

Taking a BET on hedgehog

July 31, 2014 7:00 AM UTC

Stanford University School of Medicine researchers have uncovered an interplay between BET bromodomain proteins and the hedgehog pathway that opens up additional oncology real estate for BET inhibitors.1 The inhibitors could be among the first molecules to work in hedgehog-driven cancers that no longer respond to smoothened inhibitors or other pathway modulators.

Ever since BET bromodomains emerged as therapeutic targets, corporate and academic groups have linked the epigenetic readers to long-standing cancer pathways such as c-Myc (MYC) and, more recently, androgen receptor signaling.2...